Tel: +86 (0)571 8102-5280 Email: sales@molcore.com
220246-81-1 | OR-1896

OR-1896 NLT 98%

SKU : MC541572

CAS Number : 220246-81-1

Molecular Formula : C13H15N3O2 | Molecular Weight : 245.28

Quote Request
Purity NLT 98%
Storage at 20ºC 2 years

* The above information is for reference only.

* If the product has intellectual property rights, a license granted is must or contact us.

Chemical Name OR-1896
CAS Number 220246-81-1
MDL Number MFCD09952125
Molecular Formula C13H15N3O2
Molecular Weight 245.28
Introduction of 220246-81-1 :

OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K+ channels and has Ca2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation[1]. IC50 & Target: K+ channels; PDE III[1] In Vitro: There are many evidences has accumulated and revealed a variety of beneficial pleiotropic effects OR-1896. OR-1896 evokes prominent vasodilatory responses, activation of ATP-sensitive sarcolemmal K+ channels of smooth muscle cells appears as a powerful vasodilator mechanism. Additionally, activation of ATP-sensitive K+ channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection[1]. In Vivo: During the metabolism of Levosimendan approximately 5% of the drug is converted to the metabolite OR-1855 in the large intestine, and then acetylated in the liver to form the active metabolite OR-1896. Binding to plasma proteins is 98% for Levosimendan but only 40% for OR-1896. Unlike Levosimendan, which has an elimination half-life of 1-1.5 h, the half-life of OR-1896 is about 75 to 80 h allowing cardiovascular effects to persist up to 7 to 9 days after discontinuation of a 24-hour infusion of levosimendan. The pharmacokinetic of the parent drug is unaltered in subjects with severe renal impairment or with moderate hepatic impairment, whereas the elimination of its metabolites (OR-1896) can be prolonged[1].

Related Products